- Home
- KPTI vs INVE Comparison
KPTI vs INVE Comparison
Compare KPTI & INVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPTI
- INVE
- Stock Information
- Founded
- KPTI 2008
- INVE 1990
- Country
- KPTI United States
- INVE United States
- Employees
- KPTI N/A
- INVE N/A
- Industry
- KPTI Biotechnology: Pharmaceutical Preparations
- INVE Computer peripheral equipment
- Sector
- KPTI Health Care
- INVE Technology
- Exchange
- KPTI Nasdaq
- INVE Nasdaq
- Market Cap
- KPTI 44.5M
- INVE 74.2M
- IPO Year
- KPTI 2013
- INVE 1997
- Fundamental
- Price
- KPTI $4.21
- INVE $3.50
- Analyst Decision
- KPTI Strong Buy
- INVE Strong Buy
- Analyst Count
- KPTI 7
- INVE 3
- Target Price
- KPTI $45.43
- INVE $6.50
- AVG Volume (30 Days)
- KPTI 95.1K
- INVE 99.0K
- Earning Date
- KPTI 08-05-2025
- INVE 08-07-2025
- Dividend Yield
- KPTI N/A
- INVE N/A
- EPS Growth
- KPTI N/A
- INVE N/A
- EPS
- KPTI N/A
- INVE 3.12
- Revenue
- KPTI $142,126,000.00
- INVE $25,239,000.00
- Revenue This Year
- KPTI $2.09
- INVE N/A
- Revenue Next Year
- KPTI $12.90
- INVE $9.00
- P/E Ratio
- KPTI N/A
- INVE $1.12
- Revenue Growth
- KPTI 1.19
- INVE N/A
- 52 Week Low
- KPTI $3.51
- INVE $2.86
- 52 Week High
- KPTI $16.95
- INVE $4.35
- Technical
- Relative Strength Index (RSI)
- KPTI 41.48
- INVE 63.68
- Support Level
- KPTI $4.23
- INVE $3.10
- Resistance Level
- KPTI $5.14
- INVE $3.61
- Average True Range (ATR)
- KPTI 0.38
- INVE 0.14
- MACD
- KPTI 0.04
- INVE 0.04
- Stochastic Oscillator
- KPTI 24.45
- INVE 79.25
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
About INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.